EXPANDED SCOPE for Parent Grant Entitled, "Peer Recovery Support Services for Individuals
The United States is experiencing an unprecedented opioid epidemic. Medications for opioid use disorder (MOUD), such as methadone, buprenorphine, and extended-release naltrexone, are the recommended standard of care. There are, however, many barriers to MOUD initiation so that only a minority of individuals who could b
| Condition(s) | Opioid Use Disorder |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The United States is experiencing an unprecedented opioid epidemic. Medications for opioid use disorder (MOUD), such as methadone, buprenorphine, and extended-release naltrexone, are the recommended standard of care. There are, however, many barriers to MOUD initiation so that only a minority of individuals who could benefit from MOUD treatment ever receive it. Even among individuals presenting to a residential level of specialty SUD care, only about 20% of individuals with OUD initiate MOUD leaving them at a higher risk of opioid relapse, overdose, and death. Thus, the goal of this expansion of scope pilot study is to address this gap by modifying our currently R34-funded intervention (RFA-DA-22-034; Project # 1R34DA057627-01) that leverages the impact of peer recovery support services (P |
| Who can participate | Inclusion Criteria: * Age 18+ (inclusive) * Meets diagnostic criteria for OUD * Currently seeking inpatient treatment at Maryland Treatment Centers program * English speaking * Willing and able to provide informed consent * Able to obtain MOUD through insurance. Exclusion Criteria: * Having been prescribed and taken a maintenance dose of sublingual buprenorphine or methadone within 14 days of entering the current inpatient treatment episode * received a dose of XR-buprenorphine or XR-naltrexone within 45 days of entering the current inpatient treatment episode. |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Potomac Health Foundations |
| Locations | Baltimore, Maryland, United States |
| Start date | 2024-12-01 |
| NCT ID | NCT06696157 |
| Official listing | https://clinicaltrials.gov/study/NCT06696157 |